NautaDutilh and the Netherlands Biotech Industry Association (Niaba) are pleased to inform you that we have published our report on market expectations in the Dutch biotechnology industry. In the report, we describe the major trends and developments in the sector, mainly based on the expectations voiced within the sector itself. The report gives evidence of optimism and concern in the sector.
On the one hand, it is expected that high-quality academic research in the Netherlands will lead to more activity in the future; on the other hand it looks as though the present climate is unlikely to give rise to new Dutch national champions, like Crucell. Regulation plays a role in this but it is primarily the availability of capital and the conditions prevailing on the stock market that are playing tricks with the sector. To put it in other words, there are more smaller parties with promising medicine or technology but almost all of them are trying to ally themselves with the Big Pharma companies. These take over the small companies, or sometimes they simply acquire the technology.
The report was initiated by Corporate partner Christiaan de Brauw and Intellectual Property partner John Allen of NautaDutilh, together with Jan Wisse, director of Niaba. About 90 experts from the scientific community, the investment sector, investment banks and government, including entrepreneurs in the Dutch biotech sector, took part in this quantitative survey and more than 20 in-depth interviews were conducted with key figures in Dutch industry.
Click here for the full online report.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.